Soligenix (SNGX) Proxy filing summary

Executive summary

• Focus remains on maintaining Nasdaq listing to enhance liquidity, access to capital, and strategic flexibility, with a reverse stock split and increase in authorized shares proposed to support compliance and future growth.

• Pipeline includes diversified assets in rare diseases and biodefense, with recent progress in Behçet's disease and heat-stable vaccine programs.

• Strategic alternatives such as partnerships, licensing, mergers, and acquisitions are being actively explored, though no definitive agreements have been reached.

Voting matters and shareholder proposals

• Proposals include election of five directors, reverse stock split (1-for-2 to 1-for-20), increase in authorized shares from 75M to 125M, advisory votes on executive compensation and its frequency, ratification of Cherry Bekaert LLP as auditor, and adjournment authority.

• Board recommends voting for all proposals, emphasizing the importance of the reverse split and share increase for Nasdaq compliance and strategic flexibility.

• Fractional shares from the reverse split will be paid out in cash, not rounded up.

Board of directors and corporate governance

• Board consists of five nominees with extensive experience in pharma, biotech, and academia; average age is 70, average tenure is 14.2 years.

• Three standing committees: Audit, Compensation, and Nominating & Corporate Governance, all with independent directors.

• Board leadership combines CEO and Chairman roles, with independent directors providing oversight and holding executive sessions.

• Code of ethics and insider trading policy in place; incentive compensation recoupment policy adopted in compliance with Nasdaq rules.